No profile data available.
Sagimet Biosciences Inc. (SGMT) is a healthcare company in the hepatic treatment pharmaceuticals industry, based in San Mateo, United States, with about 16 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$51.04 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $633.21 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States.
Sagimet Biosciences reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$633.21 million as of October 9, 2026.
Listed companies of a similar size in the same industry (hepatic treatment pharmaceuticals) include Mirum Pharmaceuticals, Inc. (MIRM), Inventiva S.a. (IVA), Wave Life Sciences Ltd. (WVE), Monopar Therapeutics Inc. (MNPR).